AI Drug Development Accelerates: 170+ AI-Designed Candidates in Clinical Stage, Anthropic Launches Claude Science

According to media reports, AI-powered drug development is advancing rapidly in H1 2026. Insilico Medicine announced its first AI-generated drug candidate entering Phase III clinical trials, while Anthropic released Claude Science for scientists and pharmaceutical companies and launched its own drug discovery initiative. The global market saw over 170 AI-designed or optimized drug candidates enter clinical stages, with more than a dozen advancing to Phase III trials.

Market growth is projected to accelerate significantly. According to research institutes, the global AI drug development market reached approximately $2.49 billion in 2025 and is expected to exceed $46 billion by 2035, representing a compound annual growth rate exceeding 33%. Insilico Medicine secured major partnerships valued at nearly $7 billion in H1 2026, while ByteDance initiated independent financing for its AI drug discovery unit in June. Tech giants including Amazon, Google, and OpenAI are intensifying investments in life sciences AI.